Comments on: Five Drugs To Watch (Assuming FDA Approval) http://www.pharmalot.com/2010/02/five-drugs-to-watch-assuming-fda-approval/ News, Comment and Conversation Fri, 10 Feb 2012 19:50:19 +0000 http://wordpress.org/?v=2.6.2 By: NameIt http://www.pharmalot.com/2010/02/five-drugs-to-watch-assuming-fda-approval/#comment-461973 NameIt Tue, 02 Feb 2010 04:27:20 +0000 http://www.pharmalot.com/?p=21232#comment-461973 All these new drugs provide the opportunity to create new words. Here are some options: Viaggravation--When you still can't do it. Celebrexion--A heart-breaking occasion. Plavices--Death by a thousand cuts. Lipitoro--One big, juicy lawn mower. Nexia--The wrong snacks. All these new drugs provide the opportunity to create new words. Here are some options:

Viaggravation–When you still can’t do it.

Celebrexion–A heart-breaking occasion.

Plavices–Death by a thousand cuts.

Lipitoro–One big, juicy lawn mower.

Nexia–The wrong snacks.

]]> By: Michael M. http://www.pharmalot.com/2010/02/five-drugs-to-watch-assuming-fda-approval/#comment-461953 Michael M. Tue, 02 Feb 2010 01:40:01 +0000 http://www.pharmalot.com/?p=21232#comment-461953 And the award for "Least Novel Potential Blockbuster" goes to: Qnexa, hands down. What a joke. The FDA should simply laugh such applications out of the building. And the award for “Least Novel Potential Blockbuster” goes to: Qnexa, hands down. What a joke. The FDA should simply laugh such applications out of the building.

]]> By: kyoto27 http://www.pharmalot.com/2010/02/five-drugs-to-watch-assuming-fda-approval/#comment-461915 kyoto27 Mon, 01 Feb 2010 21:29:04 +0000 http://www.pharmalot.com/?p=21232#comment-461915 Ed, Provenge is listed above as "Dendreon's controversial prostate cancer vaccine." Following the IMPACT study, I don't think there is anything 'controversial' about Provenge; but there is a lot of controversay around Dendreon and those who tried to kill the company and Provenge. In short, the numbers for Provenge all add up now and 'controversial' prostate cancer drug misses what Provenge is really all about--a paradigm shift in how PCa and cancer will be treated in the future. Ed, Provenge is listed above as “Dendreon’s controversial prostate cancer vaccine.” Following the IMPACT study, I don’t think there is anything ‘controversial’ about Provenge; but there is a lot of controversay around Dendreon and those who tried to kill the company and Provenge. In short, the numbers for Provenge all add up now and ‘controversial’ prostate cancer drug misses what Provenge is really all about–a paradigm shift in how PCa and cancer will be treated in the future.

]]> By: Josh http://www.pharmalot.com/2010/02/five-drugs-to-watch-assuming-fda-approval/#comment-461824 Josh Mon, 01 Feb 2010 13:37:38 +0000 http://www.pharmalot.com/?p=21232#comment-461824 Pradaxa, from Boehringer Ingelheim, may actually be approved before Xarelto. In the end it may help the consumer, as prices may be a little lower. Pradaxa, from Boehringer Ingelheim, may actually be approved before Xarelto. In the end it may help the consumer, as prices may be a little lower.

]]>